Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.

Momoko TakahashiYukinori OzakiRika KizawaJun MasudaKentaro SakamakiKeiichi KinowakiTaro UmezuChihiro KondohYuko TanabeNobuko TamuraYuji MiuraTakashi ShigekawaHidetaka KawabataNoriyuki BabaHaruo IguchiToshimi Takano

Published in: BMC cancer (2019)

We found the AFF events in 5 patients (1.8%) among 277 cancer patients who had received monthly denosumab (120 mg) treatment. Long-term denosumab treatment and prior zoledronic acid treatment were identified as risk factors for the development of AFF.

Keyphrases

systematic review
bone mineral density
newly diagnosed
ejection fraction
papillary thyroid
prognostic factors
mesenchymal stem cells
meta analyses
peritoneal dialysis
lymph node metastasis
smoking cessation